SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo

Sean G. Buchanan, Jorg Hendle, Patrick S. Lee, Christopher R. Smith, Pierre Yves Bounaud, Katti A. Jessen, Crystal M. Tang, Nanni H. Huser, Jeremy D. Felce, Karen J. Froning, Marshall C. Peterman, Brandon E. Aubol, Steve F. Gessert, J. Michael Sauder, Kenneth D. Schwinn, Marijane Russell, Isabelle A. Rooney, Jason Adams, Barbara C. Leon, Tuan H. DoJeff M. Blaney, Paul A. Sprengeler, Devon A. Thompson, Lydia Smyth, Laura A. Pelletier, Shane Atwell, Kevin Holme, Stephen R. Wasserman, Spencer Emtage, Stephen K. Burley, Siegfried H. Reich

Research output: Contribution to journalArticlepeer-review

109 Scopus citations

Fingerprint

Dive into the research topics of 'SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo'. Together they form a unique fingerprint.

Medicine & Life Sciences